Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.


NJ Department of Health Recognizes National Blood Donor Month by Encouraging Residents to Make a Difference Through Blood Donation

Blood GiveTrenton, NJ, January 4, 2017 — During a time when blood donations usually decline due to the busy end of year holidays, the Department of Health encourages people to give blood in January when this lifesaving resource is typically in short supply.

“National Blood Donor Month is an excellent time to make a blood donation and make a significant difference in someone’s life.  Blood is needed 365 days a year – not just during disasters,” said Health Commissioner Cathleen D. Bennett. “This is a great opportunity for people to start the year on a positive note.” Continue reading

FDA Advises Testing for Zika Virus in All Donated Blood and Blood Components in the U.S.

FDA blueWashington, DC, August 28, 2016 — As a further safety measure against the emerging Zika virus outbreak, the U.S. Food and Drug Administration  (FDA) on Friday issued a revised guidance recommending universal testing of donated Whole Blood and blood components for Zika virus in the U.S. and its territories.

“There is still much uncertainty regarding the nature and extent of Zika virus transmission,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research.  “At this time, the recommendation for testing the entire blood supply will help ensure that safe blood is available for all individuals who might need transfusion.” Continue reading

Rowan University Researchers Announce Blood-based Biomarkers for Early Detection, Diagnosis and Staging of Parkinson’s

Rowan University logoStratford, NJ, October 21, 2015 — In a study involving nearly 400 subjects, researchers from the Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., have demonstrated that a blood test they developed can detect early-stage Parkinson’s disease.

Using human protein microarrays, the researchers identified a panel of blood-borne autoantibodies that act as potential biomarkers to detect early-stage Parkinson’s disease with an overall accuracy of 87.9 percent (94.1 percent sensitivity and 85.5 percent specificity), and an accuracy rate of 97.5 percent in differentiating between early and mild-moderate stages of the disease. Continue reading